OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian CancerTopline results to be ...
A special first birthday celebration was held at the Daegu Cha Hospital Infertility Center on the 20th. The protagonists were twins Kim Min-jung (female) and Min-seo (male), siblings of Jeong Ji-young ...
To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved ...
When activated in ovarian cancer cells, the receptor for the body's primary stress hormone alters the tumor environment in ...
Women with endometriosis have an elevated risk of developing epithelial ovarian cancer, but, when they do develop it, they ...
The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian cancer, a population where achieving long-lasting bene ...
Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the ...
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results